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Analysis of a cDNA clone derived from retrovirus-transformed rat fibroblasts has recently suggested that the
mature 50-amino-acid form of transforming growth factor a (TGFa) is derived from a 159-amino-acid
transmembrane precursor by proteolytic cleavage. To understand the processing of the TGFa precursor
molecule in more detail, we have expressed this protein in baby hamster kidney (BHK) fibroblasts under
control of the metal-ion-inducible metallothionein promoter and characterized the expressed precursor with
site-specific antipeptide antibodies. One of the BHK transfectants, termed 5:2, expressed the TGFa mRNA in
a cadmium- and zinc-inducible manner. The TGFa precursor protein was detected by immunoprecipitation
analysis of radiolabeled cell cultures. In the induced 5:2 cells, a polypeptide ofMr 13,000 to 17,000 was readily
identified by peptide antisera made to three different regions of the TGFa precursor protein. No such protein
species were observed in BHK cells treated with cadmium and zinc or in uninduced 5:2 cells. However, two cell
lines known to produce TGFa naturally, Leydig testicular tumor cells and Snyder-Theilan feline sarcoma
virus-transformed Fisher rat embryo fibroblasts, possessed detectable levels of immunologically related Mr
13,000 to 17,000 proteins. Cell fractionation studies indicate that the Mr 13,000 to 17,000 species expressed in
induced 5:2 cells is membrane associated, consistent with predictions based on the cDNA sequence of the TGFa
precursor. Media conditioned by induced 5:2 cells contained epidermal growth factor receptor-competing
activity, which, upon size fractionation, was similar in size to the mature processed form of TGFa. These data
show that these nontransformed BHK cells possess the ability to process the TGFa precursor molecule into its
native form.
Transforming growth factor a (TGFa) is a small polypep-
tide, of approximately 50 amino acids, which appears to be
structurally and functionally related to epidermal growth
factor (EGF) (15, 16). These polypeptides show significant
sequence homology and appear to have evolved by gene
duplication from a common ancestral molecule (15). TGFa
and EGF compete for binding to the same cell surface
receptor, the EGF receptor, and activate the associated
tyrosine kinase activity of the receptor molecule (17, 18).
Although these growth factors are potent mitogens in tissue
culture, recent reports have suggested that TGFa may have
different biological properties from those of EGF. TGFa has
been reported to be more potent at promoting calcium
release from rat fetal long bones (6, 7) and as an angiogenesis
factor (20).
TGFa, initially identified in the medium of retrovirus-
transformed rodent cells (1, 26, 27; for reviews, see refer-
ence 24 and D. R. Twardzik and J. R. Ranchalis, UCLA
Symp. Bone Cartilage, in press), is expressed in a variety of
human tumors and tumor cell cultures (16, 23) and is thought
to play a role in the malignancy process. Analysis of the
cloned TGFa cDNA has revealed some interesting features
regarding its expression. As is true of several other growth
factors, TGFa appears to be processed from a larger precur-
sor molecule. In the rat and the human, the precursors are
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159 and 160 amino acids, respectively, and each contains a
typical leader sequence and an extremely hydrophobic do-
main resembling a transmembrane region (2, 11). This led to
the prediction that the mature 50-amino-acid form of TGFa
is derived by proteolytic release from a membrane-bound
precursor molecule. Of particular interest is the finding that
proteolysis occurs at unique Ala-Val-Val sequences and is
most probably mediated by a protease having elastase-type
specificity (11; D. C. Lee, T. M. Rose, N. R. Webb, D. R.
Twardzik, J. R. Ranchalis, H. Marquardt, and G. J. Todaro,
Perspect. Med. [R. Soc. Lond. Symp.], in press). The fact
that an unusual protease is involved in the processing of the
precursor raises the possibility that proteolysis is a regula-
tory event in the generation of the mature growth factor.
Moreover, the marked sequence conservation of the entire
precursor that is evident in a comparison of the human and
rat cDNAs may suggest that the precursor has functions
distinct from those of the mature growth factor.
To understand the structure and processing of the TGFa
precursor in more detail, we have constructed an expression
vector that places a portion of the rat TGFa cDNA which
encodes the complete TGFa precursor molecule under the
control of the inducible mouse metallothionein promoter.
This construct has been introduced into baby hamster kid-
ney (BHK) fibroblasts, and the precursor protein produced
in these cells has been characterized with site-specific
antipeptide antibodies. Our results demonstrate that the
TGFa precursor is a membrane-associated polypeptide with
Mr 13,000 to 17,000 that is proteolytically processed in BHK
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fibroblasts to release a mature Mr 6,000 TGFa form into the
culture medium.
MATERIALS AND METHODS
Cell culture and radioactive labeling. Fisher rat embryo
fibroblast (FRE) cells and their Snyder-Theilen feline sar-
coma virus-transformed counterparts were from previously
described clones (27). Leydig testicular tumor cells were
generously provided by Greg Mundy. BHK fibroblasts were
provided by Richard Palmiter. Leydig tumor cells were
grown in RPMI 1640 supplemented with 15% fetal bovine
serum. All other cells were grown in Dulbecco modified
Eagle medium containing 10% fetal bovine serum.
Confluent cultures of cells were labeled with [35S]cysteine
(>1,000 Ci/mmol; New England Nuclear Corp.) in cysteine-
free Dulbecco modified Eagle medium containing 5% dia-
lyzed fetal bovine serum. FRE, ST-FeSV-transformed FRE,
and Leydig tumor cells were labeled at 500 uCi/ml. For
experiments involving BHK cells or the 5:2 transfectants,
cells were induced with 2 ,uM cadmium sulfate and 100 ,uM
zinc chloride prior to being labeled. Following a 6- to 10-h
induction period, cells received cysteine-free DME supple-
mented with 5% dialyzed fetal bovine serum, 200 ,uCi of
[35S]cysteine per ml, and an equivalent amount of metal ion
inducer.
Construction of the metaflothionein-rat TGFa plasmid. The
TGFa expression vector, was constructed by using plasmid
EV142 (13), which contains the mouse metallothionein 1
promoter fused to the 3' untranslated region of the human
growth hormone gene (kindly provided by Richard
Palmiter). The mouse metallothionein 1 sequence is con-
tained in an 800-base-pair (bp) fragment which extends from
the 5' flanking sequence through the promoter and includes
the first 64 bp of exon 1. This fragment is fused by a unique
BglII site to a 625-bp human growth hormone fragment
which contains the 3' untranslated region of exon 5, the
polyadenylation signal, and 3' flanking sequences. These
fragments are contained in pBX322, a high-copy-number
derivative of pBR322 which contains an XhoI linker at about
position 3000. To generate pEV2, a 700-bp SmaI fragment
which includes the entire rat TGFa coding region was
inserted into the unique BglII site. Clones with the proper
orientation were selected, and DNA was isolated for trans-
fection.
Transfection ofBHK cells. Subconfluent BHK cells grown
in 100-mm dishes containing 10 ml of complete medium
(Dulbecco modified Eagle medium with 10% fetal bovine
serum) were transfected with 20 ,ug of pEV2 as a calcium
phosphate precipitate (28) in the presence of 1 mM chloro-
quine. After the cells had been incubated for 5 h at 37°C, the
medium was removed and replaced with 10 ml of fresh
medium. After an additional 24 h in culture, Geneticin
(G418; GIBCO Laboratories) was added to the medium at
500 ,ug/ml. Antibiotic-resistant clones were visible after 1
week; these clones were isolated and tested for their expres-
sion of TGFa mRNA by a solution hybridization assay
(D. C. Lee, K. J. Ibbotson, S. M. D'Souza, C. Reasner, G.
Carpenter, D. R. Twardzik, G. J. Todaro, and G. R.
Mundy, J. Clin. Invest., in press).
RNA isolation and Northern blot analysis. RNA was iso-
lated by homogenization of tissue or cells in 4 M guanidine
thiocyanate and sedimentation through 5.7 M CsCl (5).
Northern blots were performed essentially as described
previously (10) with poly(A)+ RNA selected by chromatog-
raphy on oligo(dT)-cellulose.
Production of antipeptide antibodies. Peptides were syn-
thesized by solid-phase techniques on a Beckman automated
instrument (4) and purified by preparative high-pressure
liquid chromatography. The composition of the peptides was
confirmed by amino acid analysis. Purified peptides were
coupled to bovine -y-globulin through the cysteine residue
and used to immunize New Zealand White rabbits (3).
Immunization schedules were as described previously (3).
Immunoprecipitation analysis. Radiolabeled cell cultures
were lysed in detergent-containing buffer (20 mM Tris hy-
drochloride [pH 7.4], 150 mM NaCl, 0.5% sodium deoxy-
cholate, 1.0% Nonidet P-40, 1 mM EDTA, 2 mM phenyl-
methysulfonyl fluoride, 200 kallikrein inhibitory units of
aprotinin [Sigma Chemical Co.] per ml) and clarified by
centrifugation at 100,000 x g for 30 min at 4°C. A 100-pul
portion of lysate equivalent to 5 x 105 to 1 x 106 cells was
precleared with 10 mg of Staphylococcus aureus and then
incubated with 5 ,ul of serum at 0°C for 1 h. Immunocom-
plexes were collected on S. aureus and washed as described
previously (3). Peptide-blocking experiments were per-
formed with purified peptide. Immunoprecipitated samples
were lysed with sodium dodecyl sulfate (SDS)-containing
buffer and electrophoresed on 15% polyacrylamide or 12 to
20% gradient polyacrylamide gels (9). Radiolabeled proteins
were detected by fluorography with En3Hance (New En-
gland Nuclear).
Radioreceptor assay. The binding of 125I-labeled EGF to its
receptor was measured on monolayers of Formalin-fixed
A431 cells as previously described (1). Concentrations of
TGFa are expressed as nanogram equivalents of EGF, i.e.,
the amount required to produce an inhibition of 1251I-labeled
EGF binding equivalent to that produced by a known
amount of EGF.
Membrane fractionation. Radiolabeled cell cultures were
collected by scraping. Cells were swollen in hypotonic lysis
buffer (20 mM HEPES [N-2-hydroxyethylpiperazine-N'-2-
ethanesulfonic acid; pH 6.9], 1 mM EDTA, 2 mM phenyl-
methylsulfonyl fluoride, 200 kallikrein inhibitory units of
aprotin per ml) at 2 x 107 cells per ml for 20 min at 4°C and
Dounce homogenized. Nuclei and unbroken cells were re-
moved by centrifugation at 2,000 x g for 15 min at 40C, and
the supernatant was further fractionated into pelleting (P100)
and supernatant (S100) fractions by centrifugation at 100,000
x g. The P100 fraction was separated on discontinuous
sucrose gradients essentially as described previously (14).
For immunoprecipitation analysis, samples were adjusted to
1 x in detergent lysis buffer.
RESULTS
Expression of rat TGFoa in BHK cells. To characterize the
TGFa precursor, we prepared an expression vector (pEV2;
Fig. 1A) that places the rat TGFa cDNA under the control of
the inducible mouse metallothionein I promoter. Induced
transcription of this vector would yield a hybrid mRNA of 1
kilobase pair (kb) containing 700 base pairs (bp) of TGFa
cDNA, 64 bp of metallothionein gene, and 240 bp of the
human growth hormone segment. The last of these was
present to provide a 3' noncoding sequence and polyadenyla-
tion signal. pEV2 was cotransfected into BHK cells along
with the selectable neomycin resistance marker, and cells
resistant to G418 were isolated. Expression ofTGFa mRNA
in transfected BHK cells was determined by solution hybrid-
ization as described previously (10). One transfectant
(termed 5:2) was shown to express the hybrid TGFa mRNA
at high levels following induction with cadmium and zinc and
was used for further characterization.
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FIG. 1. (A) Schematic diagram showing construction of the expression vector pEV2. A 700-bp SmaI fragment of the rat TGFa cDNA
which contains the entire coding region for the TGFa precursor protein (oi and _) was inserted behind the mouse metallothionein
promoter element (MT1). A 620-bp fragment containing the 3' end of human growth hormone gene (hGH) [including the poly(A) addition
sequence] was joined to the 3' end of the rat TGFa cDNA fragment. (B) Northern blot analysis of poly(A)+ RNA with the rat TGFa cDNA
probe. Poly(A)+ RNA (5 ,g) from Leydig testicular tumor cells, normal rat liver, uninduced 5:2 cells (5:2), and 5:2 cells treated with cadmium
and zinc (5:2i) were electrophoresed on a 1% agarose-formaldehyde gel and blotted onto nitrocellulose. Hybridization and washing conditions
are described in Materials and Methods.
A Northern blot analysis of poly(A)+ RNA isolated from
5:2 cells is shown in Fig. 1B. Equivalent amounts of
poly(A)+ RNA from rat liver and Leydig testicular tumor
cells, a cell line known to produce TGFa protein, were
included for comparison. Induced 5:2 cells contained a large
amount of 1-kb mRNA that hybridized to the TGFa cDNA
probe. The levels of this hybrid 5:2 mRNA appeared to be
similar to, if not greater than, the levels observed for the
natural 4.5-kb mRNA found in Leydig cells. In contrast,
uninduced 5:2 cells contained nondetectable amounts of
TGFa mRNA. Using the solution hybridization assay, we
estimated that the hybrid TGFa mRNA was induced at least
20- to 50-fold in 5:2 cells after a 10- to 12-h exposure to
cadmium and zinc.
Immunoprecipitation of the TGFa precursor polypeptide
with site-specific antipeptide antibodies. Site-specific antibod-
ies directed toward peptide sequences within the predicted
rat TGFa precursor protein molecule (11) were generated in
rabbits by using synthetic peptides as immunogens. Figure
2A shows the peptide sequences which were used, as well as
their relative locations within the TGFa precursor polypep-
tide. The TGFa antibodies were directed toward epitopes
present within the carboxy-terminal region of the precursor
molecule and are precursor specific.
Antisera were tested for their ability to specifically immu-
noprecipitate induced proteins from [35S]cysteine-labeled
cell cultures. The results of the immunoprecipitation analy-
sis are shown in Fig. 2B. In the cadmium- and zinc-induced
5:2 cells (lanes 5:2i), prominently labeled proteins of M,
13,000 to 17,000 were readily identified by each of the
peptide antisera. This species was not identified by normal
rabbit serum and was not immunoprecipitated from control
BHK cells exposed to similar levels of cadmium and zinc
(lanes BHK) or in uninduced 5:2 cells (lanes 5:2). Further-
more, incubation of peptide antisera with synthetic peptide
immunogen prior to addition of radiolabeled cell lysate
completely abolished detection of this protein species (lane
5:2i+PEP). Two additional TGFa antisera, one directed
against a 17-amino-acid synthetic peptide constituting the
carboxy-terminus of the fully processed TGFa (12) and one
generated against the synthetic 50-amino-acid TGFa mole-
cule, identified proteins which comigrated with the Mr 13,000
to 17,000 species recognized by the precursor-specific anti-
bodies (data not shown).
SDS-polyacrylamide gel electrophoresis of immunopre-
cipitates from [35S]cysteine-labeled FRE, ST-FeSV-
transformed FRE, and Leydig testicular tumor cells are
shown in Fig. 3. Both transformed cell types, known to
produce TGFa naturally, exhibited an immunoreactive pro-
tein species which appeared to comigrate with the species
observed in 5:2 cells. This Mr 13,000 to 17,000 protein was
identified by two different TGFa antisera and in a peptide-
specific manner. Furthermore, this protein was not detected
in the nontransformed FRE cells. These results provide
strong evidence that the Mr 13,000 to 17,000 species identi-
fied in the BHK transfectants and in the ST-FeSV-
transformed FRE and Leydig cell lines is the TGFa precur-
sor and are consistent with the size (Mr 16,970) of the
precursor molecule predicted on the basis of the cloned
cDNA sequence (11). Interestingly, the Mr 13,000 to 17,000
TGFa precursor polypeptide appeared more abundant in the
transfectant BHK cell line than in either ST-FeSV-
transformed FRE or Leydig cells.
In addition to the Mr 13,000 to 17,000 protein species
identified in ST-FeSV-transformed FRE and Leydig tumor
cells, a protein of Mr 25,000 was detected in the immuno-
precipitates. This protein was present in both transformed
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FIG. 2. (A) Line diagram of the rat TGFaL precurs
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known to produce high levels of mature, fully processed
TGFa were used for comparison. Figure 4A shows the
results obtained. ST-FeSV-transformed FRE cells produced
by far the greatest amount of EGF-competing activity into
-- culture supernatants, approaching nearly 6 ng equivalents of
EGF-competing activity per ml of conditioned culture me-
dium. Induced 5:2 cells also contained competing activity,
albeit at lower levels (ca. 0.8 ng equivalents per ml of
-v- conditioned medium). Supernatants from uninduced 5:2 cells
and the parental BHK cell line treated with cadmium and
zinc produced nondetectable levels of EGF-competing ac-
tivity.
To examine the nature of the TGFa molecule secreted by
the induced 5:2 cells, conditioned medium was fractionated
over a high-pressure liquid chromatography gel permeation
column and fractions were assayed for EGF-competing
activity (Fig. 4B). The EGF-competing activity induced from
5:2 cells was detected as a Mr 6,000 protein species which
appeared to coelute with the fully processed TGFa form
found in the supernatant of ST-FeSV-transformed FRE
cells. No larger forms of TGFa were detected, indicating
that processing of the precursor was complete in these cells.
Detection of processing intermediates. Pulse-chase analysis
was used to identify processing intermediates of TGFa.
P-43K Induced 5:2 cells were pulse-labeled in cysteine-free mediaK for 15 min with [35S]cysteine and chased with complete
-25.7K media for various times. Detergent lysates were prepared,
and the TGFa precursor was immunoprecipitated with anti-
-J8.4 K TGFa137-159. Figure 5 shows the results obtained from SDS-
1-14.3K polyacrylamide gel electrophoresis of the immunoprecipi-
tates. The TGFa precursor was readily identified in the
-6.2 K induced 5:2 cells by using a 15-min labeling period. At time
zero, the TGFa precursor behaved as a polypeptide migrat-
ing on SDS-polyacrylamide gels with Mr 14,000 to 18,000.
After a 20-min chase, an increase in the size of the TGFa
precursor polypeptide from Mr 14,000 to 18,000 to Mr 15,000
to 19,000 was readily apparent. Longer chase times revealed
iorproteiln, the dramatic decrease in size of the Mr 15,000 to 19,000511UWIIIt; tilS IVL;4LIUII UIIU bfZ4UCIIL%;-- V1 byllUIVLK;l PUPLIU, IlillillUllU-
gens. Symbols: c, , functionally important regions of the
precursor. (B) Gel electrophoresis of immunoprecipitates prepared
from antipeptide antibodies. Immunoprecipitates prepared from
[35S]cysteine-labeled cells were fractionated on 12 to 20% polyacryl-
amide gradient gels and fluorographed. Cells were induced with
metal ions for 8 h and labeled for 12 h with [35S]cysteine. Antisera
used are indicated at the top of the figure. Lanes: BHKi, BHK cells
treated with cadmium and zinc; 5:2, uninduced 5:2 cells; 5:2i, 5:2
cells treated with cadmium and zinc; 5:2i + PEP, antibody was
blocked with 0.2 ,ug of synthetic peptide immunogen prior to
immunoprecipitation analysis of induced 5:2 cells. Molecular mass
markers are indicated on the right.
appeared to be identified in a peptide-specific manner. This
larger species may be related to higher-molecular-weight
forms of bioactive TGFa secreted by some tumor cell lines
(12). Alternatively, this polypeptide may represent an immu-
nologically distinct form associated with the Mr 13,000 to
17,000 TGFa precursor during immunoprecipitation. The Mr
25,000 form was not detected in the transfected BHK cells.
The TGFa precursor protein is proteolytically processed in
BHK cells. To determine whether the TGFa precursor pro-
tein was secreted or processed in the transfected BHK cells,
conditioned medium was collected from these cells and
analyzed for its ability to compete with iodinated EGF for
binding to the EGF receptor. As controls, we included the
parental BHK cells exposed to cadmium and zinc, as well as
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FIG. 3. Immunoprecipitation of TGFa from Leydig testicular
tumor and ST-FeSV-transformed FRE cells with precursor-specific
antipeptide antibodies. Confluent cultures of cells were labeled for 2
h with 0.5 mCi of [35Slcysteine per ml in cysteine-free media.
Immunoprecipitates from equivalent amounts of 3"S-labeled pro-
teins were prepared and analyzed by SDS-polyacrylamide gel elec-
trophoresis on 15% polyacrylamide gels. Molecular mass markers
(kilodaltons) are shown to the left. + PEP denotes lanes which were
preincubated with synthetic peptide prior to immunoprecipitation.
Only the bottom two-thirds of the gel is shown.
A
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FIG. 4. (A) EGF-competing activity of conditioned medium from tissue culture cells. Conditioned medium prepared as described in
Materials and Methods was tested for its ability to compete with iodinated EGF for binding to EGF membrane receptors. Competing activity
is expressed as nanogram equivalents of EGF. Abbreviations: ST, media from ST-FeSV-transformed FRE: 5:2i and BHKi, media from
cadmium and zinc-treated 5:2 and BHK cells, respectively; 5:2, media from 5:2 cells. (B) Two-milliliter equivalents of conditioned medium
from cells described above were fractionated on a Bio-Sil TSK-250 high-pressure liquid chromatography column (21.5 by 600 cm) equilibrated
in 40%o acetonitrile-0.1% TFA, (pH 1.9). Fractions collected were lyophilized and tested for EGF-competing activity. Arrows denote eluting
positions of the marker proteins: 68K, bovine serum albumin; 14K, RNase A; 6K, insulin.
species to one of Mr 13,000 to 17,000. After a 160-min chase,
the detected TGFa precursor species comigrated with the
precursor immunoprecipitated from induced 5:2 cells labeled
for 8 h (control lane), suggesting that complete processing
had occurred over this 160-min chase period. The half-life of
the precursor identified with anti-TGFa137.159 was approxi-
mately 2 h. We cannot rule out the possibility that this
apparent half-life is due to an early cleavage event involving
the carboxy-terminal epitopes used for immunoidentifica-
tion.
The TGFa precursor protein is membrane associated. The
membrane localization of the TGFa precursor was deter-
mined by cell fractionation and differential centrifugation.
Pulse 15mln
chose/ime(mrn) 0 20 40 80160 Control
43K-
Radiolabeled 5:2 cells treated with cadmium and zinc were
broken, and the microsomal fraction and soluble constitu-
ents were separated by ultracentrifugation. Both the S100
and P100 fractions from a 100,000 x g centrifugation were


















FIG. 5. Pulse-chase analysis of the TGFa precursor protein. The
5:2 cells were induced for 10 h with cadmium and zinc, incubated in
cysteine-free media for 1 h, and pulse-labeled with 1 mCi of
[355]cysteine per ml for 15 min. After pulse-labeling, cells were
incubated with complete Dulbecco modified Eagle medium for
various times, the TGFa precursor was immunoprecipitated, and
immunoprecipitates were fractionated on a 15% polyacrylamide gel.
Molecular weight markers (kilodaltons) are included on the left-hand
side of the figure. Only the bottom two-thirds of the gel is shown.
6K-
FIG. 6. (A) Microsomal fractionation of the expressed TGFa
precursor protein. The BHK and 5:2 cells were treated with cad-
mium and zinc for 8 h and labeled with [35S]cysteine for 12 h. The
P100 and S100 fractions prepared as described in Materials and
Methods were immunoprecipitated with anti-TGFLI37-15, and ana-
lyzed by gel electrophoresis on 12 to 20% gradient gels. +PEP
indicates samples which were preincubated with synthetic peptide
before being subjected to immunoprecipitation analysis. (B) Discon-
tinuous sucrose gradient analysis of the P100 fraction from panel A.
The sucrose interphases indicated were collected and im-
munoprecipitated with anti-TGFal37.151. +PEP denotes samples
blocked with synthetic peptide immunogen prior to immunoprecip-
itation analysis. The location of protein markers is shown to the left
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6A. Nearly all the immunoreactive TGFa precursor protein
was found in the P100 fraction (P100; lanes 5:2i), suggesting
a membrane association. To delineate this potential mem-
brane association further, the P100 fraction was separated by
discontinuous sucrose gradient centrifugation. In this analy-
sis, the plasma membrane fraction collects at the 20/35%
sucrose interphase, since it possesses the lowest density of
the microsomal components. Results of the immunoprecip-
itation analysis of the gradient fractions are shown in Fig.
6B. Densitometric analysis of the autoradiograph reveals
that 52% of the Mr 13,000 to 17,000 immunoreactive TGFa
precursor fractionates within the 20/35% sucrose interphase.
Marker enzyme analysis shows that 64% of the membrane-
associated 5'-nucleotidase activity (29) is located within this
sucrose fraction (data not shown). These results suggest
colocalization of the TGFa precursor with the plasmalemma
fraction.
DISCUSSION
In this study, we expressed a transfected cDNA encoding
the complete rat TGFa precursor in nontransformed BHK
fibroblasts to study the expression and processing of the
TGFa molecule. The expressed TGFa precursor protein was
identified and characterized by site-specific immunological
reagents directed toward peptide epitopes within the
carboxy end of the precursor polypeptide. A summary of our
results follows. First, the TGFa precursor was readily
identified in the transfectant BHK fibroblasts. The most
stable from of this protein behaved on SDS-polyacrylamide
gels as a diffusely migrating protein with apparent Mr 13,000
to 17,000. This value is consistent with the predicted molec-
ular weight of the precursor molecule. Second, immunoreac-
tive proteins which appear to comigrate with the TGFa
precursor detected in the BHK transfectant were found in
two cell lines, Leydig testicular tumor and ST-FeSV-
transformed FRE cells, known to produce TGFa naturally,
but were not found in nontransformed FRE or BHK cells.
Third, the Mr 13,000 to 17,000 precursor molecule expressed
in the transfectant BHK cells colocalized with the
plasmalemma of fractionated cells; this result is consistent
with a proposed membrane localization of the precursor
molecule based on an analysis of the TGFa cDNA (11).
Finally, these nontransformed BHK fibroblasts were dem-
onstrated to be capable of proteolytically processing the
TGFa precursor molecule to the mature Mr 6,000 species.
Pulse-chase experiments allowed us to examine the proc-
essing of the TGFa precursor molecule in intact BHK
transfectants and to identify processing intermediates. Our
results demonstrate that the Mr 13,000 to 17,000 TGFa
precursor arises from two short-lived intermediates of Mr
14,000 to 18,000 and Mr 15,000 to 19,000. The Mr 14,000 to
18,000 polypeptide is the initial translation product observed
after a short pulse-label and is rapidly converted into the
larger, Mr 15,000 to 19,000, intermediate. This initial proc-
essing event, which results in the apparent increase in
molecular weight observed on SDS-polyacrylamide gels,
may be the result of covalent posttranslational modification
such as phosphorylation, lipidation, or carbohydrate addi-
tion. A typical N-linked glycosylation site is present in the
predicted sequence of the TGFa precursor (11). The Mr
15,000 to 19,000 TGFcx precursor intermediate is subse-
quently converted into the Mr 13,000 to 17,000 polypeptide.
This final precursor form detected by the antipeptide anti-
bodies comigrates with the TGFot precursor identified in the
BHK transfectant labeled with [35S]cysteine under normal
conditions. The loss in molecular weight of approximately
2,000 from the larger TGFa precursor intermediate is prob-
ably due to proteolysis. Antibodies directed toward the
carboxy-terminal 7 amino acids of the TGFa precursor
(anti-TGFa15-159) were also able to identify similar process-
ing intermediates (data not shown). Thus, this early stage of
proteolytic processing must occur at the amino end of the
precursor molecule. A loss in molecular weight of 2,000
would be consistent with cleavage of the 23-amino-acid
hydrophobic leader peptide predicted from the sequence of
TGFa cDNA (13).
Complete processing of the Mr 13,000 to 17,000 TGFa
precursor polypeptide into the released Mr 6,000 form of
TGFa was evident in the supernatants of the transfected
BHK fibroblasts. Media conditioned by these cells contained
TGFa activity (as measured by EGF competition) which,
upon gel permeation chromatography, cofractionated with
the fully processed 50-amino-acid TGFa form. Proteolytic
cleavage of TGFa from its precursor occurs at Ala-Val-Val
sequences and is most probably mediated by a protease
having elastase-type specificity (2, 11). The ability of
nontransformed BHK fibroblasts to completely process the
TGFa precursor indicates that these cells do express this
protease and suggests that processing is not mediated by a
tumor-specific proteolytic enzyme. It is entirely possible,
however, that the levels of this protease are elevated in the
malignant state. In this regard, it is interesting that while
ST-FeSV-transformed FRE cells secrete significantly higher
levels of the mature growth factor, they contain significantly
lower levels of the Mr 13,000 to 17,000 species. This is also
true of the Leydig tumor cells (data not shown), suggesting
that the half-life of the precursor is considerably shorter in
malignant cells than in nontransformed BHK cells.
Several size classes of TGFa have previously been ob-
served in the supernatants and extracts from tumor cells (1,
27). Although the Mr 6,000 form of TGFa has been well
characterized (15), its relationship with the larger forms of
TGFa precursor is not well documented. Linsley et al. (12)
and Ignotz et al. (8) used antipeptide sera directed toward
the carboxy terminus of the 50-amino-acid TGFa molecule
to characterize the larger secreted forms. Several molecular
weight classes of immunoreactive material were identified,
the most conspicuous of which was a polypeptide of molec-
ular weight approximately 20,000 (8, 12). Ignotz et al.
extended this analysis further and revealed that after diges-
tion with elastase, this larger precursor form of TGFa
released an Mr 6,000 polypeptide with properties of mature
TGFa (8). The relationship of this Mr 20,000 secreted
(released) form with the precursor forms detected in this
report remains to be established. Our present results indicate
that nontransformed BHK fibroblasts release only the ma-
ture, fully processed 50-amino-acid TGFa. This raises the
possibility that tumor cells process the TGFa precursor
differently from nontransformed cells, resulting in the re-
lease of larger TGFa precursor forms. The precursor-
specific antibodies described here should prove useful in
assessing the relationship of these larger secreted forms with
the TGFa precursor, as well as in characterizing the high-
molecular-weight forms of TGFa-like species previously
found in the urine of patients with disseminated cancer (21,
25).
Although much is known concerning the biological prop-
erties of TGFa, the role of this growth factor in the devel-
opment of the malignant state remains unclear. The produc-
tion ofTGFa by a variety of transformed cells (24; Twardzik
and Ranchalis, in press), as well as its occurrence in the
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urine of cancer patients (21, 25), implies that it plays an
important role in cellular transformation. Recently,
Rosenthal et al. (19) presented evidence that the expression
of the TGFa gene in nontransformed Rat-1 cells results in
the acquisition of the transformed phenotype via an
autocrine mechanism. Although we have not yet examined
in detail the phenotype of the TGFa-expressing BHK cells,
the precursor-processing capability of these nontransformed
fibroblasts represents the initial stage of an autocrine re-
sponse (22). We are currently examining the phenotype of
these cells.
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ADDENDUM IN PROOF
While this manuscript was in press, Bringman et al. (T. S.
Bringman, P. B. Lindquist, and R. Derynk, Cell 48:429-440,
1987) presented similar evidence describing the processing
of the TGFa precursor.
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